Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06631053 · ClinicalTrials.gov registry record · NA

FIT Exercise in 30d of ULLS-induced Muscle Disuse

A NA study of Muscle Weakness and Muscle Atrophy, sponsored by Lance Bollinger.

Recruiting
Registry status
NA
Development phase
16
Enrollment target
1
Study location

NCT06631053 is a NA study of Muscle Weakness and Muscle Atrophy that is actively recruiting participants, run by Lance Bollinger. The registered enrollment target is 16 participants, below the 74-participant average among 25 other Muscle Weakness trials with a reported enrollment target (78% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06631053, a NA study of Muscle Weakness and Muscle Atrophy, is actively recruiting participants, sponsored by Lance Bollinger.

RECRUITING
Registry status
NA
Development phase
16 participants
Enrollment target
1
Study location

Study Summary

This study aims to determine how flywheel-based inertial training (FIT) implemented according to principles of velocity-based training (VBT) and High-Intensity Interval Training (HIIT) affects disuse-induced physical de-conditioning including loss of voluntary muscle strength, aerobic capacity, and balance regulation.

Interventions

  • OTHER No Exercise
  • OTHER velocity-based FIT (VBFIT)

Study Locations (1)

Kentucky

  • University of Kentucky - Lexington

Trial Details

FieldValue
Enrollment Target 16 participants
Start Date 2024-10-23
Est. Completion 2026-09-01
Phase NA

Sponsor

Lance Bollinger

2 total trials

What the Registry Record Tells You About NCT06631053

The ClinicalTrials.gov registry entry for NCT06631053 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 74-participant average among 25 other Muscle Weakness trials with a reported enrollment target (78% lower). The listed sponsor is Lance Bollinger, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Muscle Weakness appearing as the primary indexed condition, and to 2 interventions - of which No Exercise is the first listed.

NCT06631053 reports 1 study location spanning 1 distinct geographic area - top geographies include Kentucky.

Frequently Asked Questions

What is clinical trial NCT06631053 about?

NCT06631053 is a clinical study titled "FIT Exercise in 30d of ULLS-induced Muscle Disuse". This study aims to determine how flywheel-based inertial training (FIT) implemented according to principles of velocity-based training (VBT) and High-Intensity Interval Training (HIIT) affects disuse-induced physical de-conditioning including loss of voluntary muscle strength, aerobic capacity, and ...

What is the current status of trial NCT06631053?

This trial is currently recruiting. It is a NA study. The enrollment target is 16 participants. The study started on 2024-10-23. Estimated completion is 2026-09-01.

What conditions does trial NCT06631053 study?

This clinical trial studies the following conditions: Muscle Weakness, Muscle Atrophy.

What interventions are being tested in trial NCT06631053?

The interventions under investigation include: No Exercise (OTHER), velocity-based FIT (VBFIT) (OTHER).

Who is sponsoring clinical trial NCT06631053?

This trial is sponsored by Lance Bollinger, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06631053 being conducted?

This trial has 1 study location across Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Muscle Weakness

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.